Abstract

Pain Management in Patients Undergoing Cytoreductive Surgery with or without HIPEC: An Audit of Analgesic Practices and Outcomes

---

Abstract

Cytoreductive surgery (CRS) with or without hyperthermic intraperitoneal chemotherapy (HIPEC) is a complex oncologic procedure used in the management of advanced peritoneal surface malignancies. The procedure carries a significant postoperative pain burden due to extensive peritoneal dissection and inflammation. Effective analgesia is therefore essential to facilitate early mobilisation and optimise recovery. Enhanced Recovery After Surgery (ERAS) guidelines recommend thoracic epidural analgesia as first-line therapy, supported by multimodal, opioid-sparing strategies1,2. This audit evaluated epidural utilisation, block adequacy, and postoperative analgesic outcomes in CRS ± HIPEC patients, aiming to identify opportunities for service improvement and guide the development of a local CRS ± HIPEC perioperative protocol.

Keywords: cytoreductive surgery, hyperthermic intraperitoneal chemotherapy, advanced peritoneal surface malignancies, analgesia, recovery after surgery

How to Cite:

Thomson, C., Nawarathna, D., MacHale, J., (2026). Pain Management in Patients Undergoing Cytoreductive Surgery with or without HIPEC: An Audit of Analgesic Practices and Outcomes. In: Abstracts of EBPOM Dingle, Ireland Conference 2025: 16-18 September 2025, Dingle, Ireland. Advances in Perioperative Care: UCL Press; 2026. Pp 1-4. DOI: 10.14324/111.444/apoc.ebpomdingle25.a4

Rights: Author, [2026]